ARCHIVES

Advisors Reaffirm Survival As Standard For full FDA Approval Of Cancer Drugs

This article is from The Cancer Letter archive.

Vol. 25 No. 24 | June 16, 1999

Download PDF Visit The Full Archive

Related Articles

NCI Begins PLCO Screening Trial

November 26, 1993

DCE Board Approves Recompetitions, Program Announcement For Research On Fish

July 7, 1989

NCI-Approved Clinical Trials Listed For January

January 28, 2005

In Brief: Harmon Eyre Heads Medical Affairs, Research As Third Member OF ACS National Office “Troika”

April 16, 1993

Blinatumomab Shows Response In Adults with Refractory ALL

May 25, 2012

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

January 21, 2005